Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders

Last updated: August 23, 2023
Sponsor: Emory University
Overall Status: Completed

Phase

3

Condition

Substance Abuse

Stimulant Use Disorder

Mood Disorders

Treatment

Oxygen (15-O) Water

Sham Stimulation

Non invasive VN stimulation (nVNS)

Clinical Study ID

NCT04556552
IRB00117320
UG3DA048502
  • Ages 18-80
  • All Genders

Study Summary

Subjects in this study will be patients with opioid use disorders (OUDs) based on DSM-5 criteria recruited from the greater Atlanta metropolitan region. Recruitment will be from treatment programs in the greater Atlanta Metropolitan Region including the DeKalb Community Service Board residential, detoxification and other treatment programs which with over 30,000 patient visits per year represents the largest treatment program in one of two urban counties in greater Atlanta.

This trial involves a second phase after completing an exploratory study in 20 patients with OUDs to assess different timing parameters of nVNS effects on sympathetic measures and symptoms of craving, as well as modelling to verify and iteratively refine the methods for vagal nerve stimulation. The investigators in this trial will then apply nVNS comparing active (N=10) to sham (N=10) in OUD patients recently started on medication, looking at opioid craving, brain functional response with HR-PET, and cardiovascular and inflammatory biomarker responses to imagery-induced opioid drug craving.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Inclusion Criteria: Subjects aged 18 and over who meet criteria for OUDs based on the Structured ClinicalInterview for DSM-5 (SCID) interview and are stable on medication treatment.

Exclusion

Exclusion Criteria:

  1. Positive pregnancy test
  2. Meningitis
  3. Traumatic brain injury
  4. Neurological disorder or organic mental disorder
  5. History of loss of consciousness greater than one minute
  6. Current pregnancy or breastfeeding for women
  7. Current or lifetime history of schizophrenia, schizoaffective disorder, or bulimia,based on the SCID
  8. A history of serious medical or neurological illness, such as cardiovascular,gastrointestinal, hepatic, renal, neurologic or other systemic illness
  9. Evidence of a major medical or neurological illness that is based on the clinicaljudgment of the study psychiatrist
  10. Active implantable device (i.e. pacemaker)
  11. Carotid atherosclerosis
  12. Cervical vagotomy

Study Design

Total Participants: 20
Treatment Group(s): 3
Primary Treatment: Oxygen (15-O) Water
Phase: 3
Study Start date:
November 13, 2020
Estimated Completion Date:
September 13, 2022

Study Description

Subjects in this study will be patients with opioid use disorders (OUDs) based on DSM-5 criteria recruited from the greater Atlanta metropolitan region. The metropolitan Atlanta area has about 2,623,744 persons age 12 or older. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), 109,777 (4.18%) have non-medical use of prescription pain relievers, and 48,302 are estimated to have an opioid use disorder. This DSMP describes the UG3 phase which will study patients with OUDs early in the course of treatment. The Go-No Go criteria listed below have to be met to proceed to the UH3. Recruitment will be from treatment programs in the greater Atlanta Metropolitan Region including the DeKalb Community Service Board residential, detoxification and other treatment programs which with over 30,000 patient visits per year represents the largest treatment program in one of two urban counties in greater Atlanta.

The first UG3 phase will involve an exploratory study in 20 patients with OUDs to assess different timing parameters of nVNS effects on sympathetic measures and symptoms of craving, as well as modelling to verify and iteratively refine our methods for vagal nerve stimulation. The investigators in this trial will then apply nVNS in a pilot study comparing active (N=10) to sham (N=10) in OUD patients recently started on medication, looking at opioid craving, brain functional response with HR-PET, and cardiovascular and inflammatory biomarker responses to imagery-induced opioid drug craving. Brain function will be measured with high resolution positron emission tomography (HR-PET), autonomic function with wearable sensing devices, and biomarkers will be measured in blood, with an assessment of a broad range of stress responsive sympathetic, hormonal and immune markers.

Connect with a study center

  • Emory University

    Atlanta, Georgia 30322
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.